Giornale di Clinica Nefrologia e Dialisi · Published 2026-06-25 · DOI 10.33393/gcnd.2026.3718
Anna De Amici, Chiara De Liso, Anna Pisacreta, Margherita Di Naro, Lara Caldiroli, Paolo Molinari, Anna Regalia, Emilietta Brigati, Simona Verdesca, Marco Maggi, Matteo Tommaso Righi, Michele Filippi, Giuseppe Castellano, Carlo Alfieri
Anemia is one of the most common complications in patients undergoing kidney transplantation, with an estimated prevalence between 30% and 50%, especially in the first six months after transplantation. The pathogenesis of anemia in these patients is multifactorial, related to chronic inflammation, disorders of iron metabolism, myelosuppression from several immunosuppressive drugs, and hormonal and metabolic alterations. The clinical implications of anemia in kidney transplants are significant: it is a negative prognostic factor for patient and transplant survival, significantly affecting cardiovascular risk and quality of life. This review analyzes in detail the pathogenic mechanisms of anemia in the post-transplant context, illustrating their clinical impact and providing an updated overview of currently available therapeutic strategies, with a focus on new molecules belonging to the class of prolyl-hydroxylase inhibitors (HIF-PHi), which are revolutionizing the therapeutic approach to anemia secondary to renal failure.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Amici, A., Liso, C., Pisacreta, A., et al. (2026). From iron to HIF-PH inhibitors: rethinking anemia management after kidney transplant. Giornale di Clinica Nefrologia e Dialisi. https://doi.org/10.33393/gcnd.2026.3718